MedPath

Study of the effects of AMG(alpha1-micoroglobulin) reduction rates on the survival, complications and prognosis in dialysis patients

Not Applicable
Conditions
Chronic hemodialysis in out-patients
Registration Number
JPRN-UMIN000038457
Lead Sponsor
Osaka City University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
4000
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with malignancy, clinically overt infection, acute or severe illness, dementia and dialysis re-initiation after functional loss of transplanted kidney.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survival and cardiovasculardisease events
Secondary Outcome Measures
NameTimeMethod
Survival or cardiovascular disease events
© Copyright 2025. All Rights Reserved by MedPath